Pages that link to "Q24534620"
The following pages link to Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 (Q24534620):
Displaying 50 items.
- HIV-1 entry inhibitors: an overview (Q24645525) (← links)
- Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent (Q24656023) (← links)
- The design of drugs for HIV and HCV (Q28259321) (← links)
- HIV entry inhibitors: mechanisms of action and resistance pathways (Q28296162) (← links)
- V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies (Q28469283) (← links)
- Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure (Q28477257) (← links)
- Estimating the Threshold Surface Density of Gp120-CCR5 Complexes Necessary for HIV-1 Envelope-Mediated Cell-Cell Fusion (Q28478341) (← links)
- Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study (Q28481687) (← links)
- Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections. (Q30359545) (← links)
- Closing the door to human immunodeficiency virus. (Q30428089) (← links)
- The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors (Q30486707) (← links)
- Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo (Q33455862) (← links)
- Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism. (Q33759112) (← links)
- Drug interactions with new and investigational antiretrovirals (Q33801821) (← links)
- Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). (Q33822912) (← links)
- Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing (Q33951977) (← links)
- Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor Use (Q33961704) (← links)
- Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents (Q34038718) (← links)
- Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. (Q34216388) (← links)
- New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection (Q34568280) (← links)
- Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands. (Q34571010) (← links)
- HIV entry inhibitors and their potential in HIV therapy (Q34595921) (← links)
- Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors (Q34597465) (← links)
- A small set of succinct signature patterns distinguishes Chinese and non-Chinese HIV-1 genomes (Q34634310) (← links)
- HIV entry inhibitors. (Q34654433) (← links)
- Response normalized liquid chromatography nanospray ionization mass spectrometry (Q34674281) (← links)
- Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. (Q34682512) (← links)
- Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate (Q34757951) (← links)
- The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV (Q34939533) (← links)
- A diagnostic HIV-1 tropism system based on sequence relatedness (Q34983107) (← links)
- CCR5 conformations are dynamic and modulated by localization, trafficking and G protein association (Q35106596) (← links)
- Regio- and Stereoselective Syntheses of the Natural Product CCR5 Antagonist Anibamine and its Three Olefin Isomers (Q35400327) (← links)
- Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy (Q35557216) (← links)
- Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism (Q35635933) (← links)
- HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug (Q35665842) (← links)
- Oral CCR5 inhibitors: will they make it through? (Q36458354) (← links)
- Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents (Q36459685) (← links)
- CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. (Q36508062) (← links)
- Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro (Q36541747) (← links)
- Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. (Q36607127) (← links)
- Novel antiretroviral agents in HIV therapy (Q36634459) (← links)
- Recent advances in delivery systems for anti-HIV1 therapy (Q36761854) (← links)
- New antiretroviral agents (Q36790196) (← links)
- New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists (Q36823525) (← links)
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations (Q36827946) (← links)
- Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection. (Q36839725) (← links)
- HIV-1 drug resistance mutations: an updated framework for the second decade of HAART (Q36900010) (← links)
- Recent progress in antiretrovirals--lessons from resistance (Q36967857) (← links)
- Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance (Q36980738) (← links)
- HIV-1 drug-resistance and drug-dependence (Q36981758) (← links)